Javascript must be enabled to continue!
Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature
View through CrossRef
Background: The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided another treatment option for moderate to severe persistent pain. Embeda was designed to be an abuse-deterrent opioid formulation. Naltrexone is a centrally acting opioid receptor antagonist that blocks the action of opioid. When taken as directed, insignificant amount of sequestered naltrexone would reach systemic circulation, but upon tampering, the released naltrexone may blunt the euphoria of opioids, and possibly precipitate opioid withdrawal in opioid-dependent patient.Objective: To describe a case report of a 50-year-old opioid-dependent male who developed acute opioid withdrawal after taking crushed Embeda.Case report: A 50-year-old male with severe, chronic low back pain due to degenerative disc disease was referred to our clinic for pain management. He was taking ER oxycodone 80 mg tid and Roxicodone 30 mg qid prn, with inadequate pain relief. A trial of ER oxymorphone was decided, at 40 mg 1-2 doses bid. The patient returned to the clinic 1 week early, out of his ER oxymorphone. At this time, the decision to switch him to Embeda was made, at 80 mg/3.2 mg, 1-2 doses bid. The patient and his family members were counseled about risk involved with tampering with Embeda. A few hours later, our clinic was informed that the patient was brought to emergency room by ambulance, in severe opioid withdrawal. He was treated with IV fluid, antiemetics, clonidine, and IV hydromorphone. His condition improved and he was discharged home the next morning. Later on, the patient admitted that he took two prescribed Embeda within half an hour, the 1st one whole and the 2nd one crushed. He further admitted that he did so against our medical advice.Conclusion: Taking tampered Embeda may precipitate opioid withdrawal in opioid-tolerant patient. To the best of our knowledge, this is the first report of induced opioid withdrawal following consumption of crushed Embeda.
Weston Medical Publishing
Title: Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature
Description:
Background: The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided another treatment option for moderate to severe persistent pain.
Embeda was designed to be an abuse-deterrent opioid formulation.
Naltrexone is a centrally acting opioid receptor antagonist that blocks the action of opioid.
When taken as directed, insignificant amount of sequestered naltrexone would reach systemic circulation, but upon tampering, the released naltrexone may blunt the euphoria of opioids, and possibly precipitate opioid withdrawal in opioid-dependent patient.
Objective: To describe a case report of a 50-year-old opioid-dependent male who developed acute opioid withdrawal after taking crushed Embeda.
Case report: A 50-year-old male with severe, chronic low back pain due to degenerative disc disease was referred to our clinic for pain management.
He was taking ER oxycodone 80 mg tid and Roxicodone 30 mg qid prn, with inadequate pain relief.
A trial of ER oxymorphone was decided, at 40 mg 1-2 doses bid.
The patient returned to the clinic 1 week early, out of his ER oxymorphone.
At this time, the decision to switch him to Embeda was made, at 80 mg/3.
2 mg, 1-2 doses bid.
The patient and his family members were counseled about risk involved with tampering with Embeda.
A few hours later, our clinic was informed that the patient was brought to emergency room by ambulance, in severe opioid withdrawal.
He was treated with IV fluid, antiemetics, clonidine, and IV hydromorphone.
His condition improved and he was discharged home the next morning.
Later on, the patient admitted that he took two prescribed Embeda within half an hour, the 1st one whole and the 2nd one crushed.
He further admitted that he did so against our medical advice.
Conclusion: Taking tampered Embeda may precipitate opioid withdrawal in opioid-tolerant patient.
To the best of our knowledge, this is the first report of induced opioid withdrawal following consumption of crushed Embeda.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Safety of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules: Review of postmarketing adverse events during the first year
Safety of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules: Review of postmarketing adverse events during the first year
Background: EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules, indicated for management of chronic, moderate-tosevere pain, contain pellets of morph...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Clinical pharmacology of morphine in infants and children
Clinical pharmacology of morphine in infants and children
Morphine is used to treat pain, for treatment of opioid dependence, and neonatal abstinence syndrome. Morphine is modestly absorbed from the gastrointestinal tract whereas after re...
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract
Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
ABSTRACT
Opioid addiction is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative af...
Chest Wall Hydatid Cysts: A Systematic Review
Chest Wall Hydatid Cysts: A Systematic Review
Abstract
Introduction
Given the rarity of chest wall hydatid disease, information on this condition is primarily drawn from case reports. Hence, this study systematically reviews t...

